Investor Conference Call on Xarelto COMPASS Data at ESC Congress 2017
Monday, August 28, 2017
Start approx. 1:30 p.m. CEST (11:30 a.m. UTC)
Full data from the Phase III COMPASS Study with Xarelto (Rivaroxaban) have been featured in Hot Line presentations at ESC Congress 2017 on August 27, 2017 in Barcelona, Spain. On this occasion we hosted a conference call for investors and analysts on August 28, 2017.
Dr. Jörg Möller
Head of Global Development at Pharmaceuticals
Dr. Frank Misselwitz
Head of the Therapeutic Area Thrombosis and Hematology
Dr. Jörg Möller, Head of Global Development at Pharmaceuticals
Dr. Frank Misselwitz, Head of the Therapeutic Area Thrombosis and Hematology
Oliver Maier, Head of Bayer Investor Relations
You can also play the audio recording on your mobile device.
|Presentation Charts||Download PDF collect (947 KB)|
|Transcript||Download PDF collect (64 KB)|